Showing results (111-120 of 201) with videos related to
Sort By:
Pageof 21
The Oncologist|August 4, 2020
High Serum Vitamin B12 Levels Associated with C-Reactive Protein in Older Patients with CancerAnne-Laure Couderc, Eddy Puchades, Patrick Villani, et al.Journal for Immunotherapy of Cancer|August 4, 2025
Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung studyFrancois Ghiringhelli, Yaacov R Lawrence, Enriqueta Felip, et al.Journal of Geriatric Oncology|July 31, 2021
Functional status in older patients with cancerAnne-Laure Couderc, Pierre Suchon, Bérengère Saliba-Serre, et al.European Journal of Cancer (Oxford, England : 1990)|February 25, 2018
Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group surveyAntonin Levy, Corinne Faivre-Finn, Baktiar Hasan, et al.Journal of Cancer Research and Clinical Oncology|August 25, 2023
Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancerHélène Doubre, Laurent Greillier, Grégoire Justeau, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 2, 2021
A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLCJyoti Malhotra, Petros Nikolinakos, Ticiana Leal, et al.Lung Cancer (Amsterdam, Netherlands)|August 10, 2018
The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancerKevin Jao, Pascale Tomasini, Suzanne Kamel-Reid, et al.The Lancet. Oncology|May 14, 2018
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trialVanesa Gregorc, Rabab M Gaafar, Adolfo Favaretto, et al.BMC Cancer|December 17, 2014
Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III studyIsabelle Borget, Maurice Pérol, David Pérol, et al.European Journal of Cancer (Oxford, England : 1990)|November 1, 2019
EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic diseaseAntonin Levy, Lizza E L Hendriks, Thierry Berghmans, et al.Pageof 21